An observational study in Major Depressive Disorder, Bi-Polar Disorder and ADHD, sponsored by QuantalX Neuroscience. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.
Sponsored by QuantalX Neuroscience · Observational
DELPhI acquisition and analysis software, a QuantalX Neuroscience development, which is designed to measure, analyze, and display brain electrical activity of human electroencephalogram (EEG), to transcranial magnetic stimulation (TMS), will be used to evaluate different psychiatric conditions.
Psychiatric conditions requiring pharmaceutical treatment include Schizophrenia and other psychotic disorders, Major depressive disorder, Bi-polar disorder, Post Traumatic Stress Disorder, Obsessive Compulsive Disorder and anxiety disorders. To date none of the psychiatric conditions mentioned diagnosis' relies on an imaging or other quantitative technique. Diagnosis and treatment prescription in the psychiatric clinic still relies on subjective reports and physician assessment of symptoms. Trans-cranial magnetic stimulation (TMS) is a noninvasive brain stimulation method that allows to study human cortical function In-vivo. Using TMS for examining human cortical functionality is enhanced by combining TMS with simultaneous registration of electroencephalograph (EEG). EEG provides an opportunity to directly measure the cerebral response to TMS, measuring the cortical TMS Evoked potential (TEP), is used to assess cerebral reactivity across wide areas of neo-cortex. Studies integrating TMS with EEG (TMS-EEG) have shown that TMS produces waves of activity that reverberate throughout the cortex. and that are reproducible and reliable thus providing direct information about cortical excitability and connectivity with excellent time resolution. By evaluating the propagation of evoked activity in different behavioral states and in different tasks, TMS-EEG has been used to causally probe the dynamic effective connectivity of human brain networks.
2,805 studies on the registry are indexed under Depressive Disorder, Major; 565 are open to participants now.
Browse Depressive Disorder, Major studies →QuantalX Neuroscience is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
study group: patients diagnosed with either Major depression, Bi-polar disorder, OCD, PTSD, ADHD or Schizophrenia,.without any psychiatric medications or with stable treatment regimen for the last 2 months.
Control group:
Eligible consecutive healthy individuals, recruited through advertisements spread in campuses and clinics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4.5. A normal neurological exam- control group.
Exclusion criteria:
1. Prior known epileptic episode. 2. History of any neurodegenerative disease. 3. Patients with history of other known brain disorder/pathology. 4. Contraindication to MR imaging.
-
Major depression, Bi-polar, schizophrenia, ADHD, OCD, PTSD
young healthy controls to serve as norm.
comparison of DELPhI parameter of Plasticity in psychiatric population to healthy norms.
Comparison of DELPhI parameters of Plasticity in patients, in comparison to healthy norms. Parameters will be analyzed for their temporal and special components.
Time frame: through study completion, an average of 1 year
comparison of DELPhI parameter of Connectivity in psychiatric population to healthy norms.
Comparison of DELPhI parameters of Connectivity in patients, in comparison to healthy norms. Parameters will be analyzed for their temporal and special components.
Time frame: through study completion, an average of 1 year
correlation between DELPhI parameters and symptom severity.
Self-control analysis of the change in DELPhI parameters following change in treatment prescription or any other treatment at different time points compared to base-line. Correlation to symptom severity will be assessed.
Time frame: through study completion, an average of 1 year
Cluster analysis of Plasticity and connectivity in relation to medical treatment and clinical diagnosis.
Cluster subjects by each plasticity and connectivity vs. medical treatment and clinical diagnosis.
Time frame: through study completion, an average of 1 year.
characterization of the change in Plasticity following change of treatment regimen
characterization of the change in Plasticity of Plasticity following change of treatment regimen.
Time frame: through study completion, an average of 1 year.
characterization of the change in Connectivity following change of treatment regimen
characterization of the change in Connectivity following change of treatment regimen.
Time frame: through study completion, an average of 1 year.
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is withdrawn, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
QuantalX Neuroscience